Agonistic antibodies to 4-1BB, OX40 and CD27 that are immune-stimulatory are being tested as potential immunotherapies for cancer patients and the efficacy of anti-4-1BB pre-clinically has been shown to depend on TRAF2-mediated NF-κB activation [54]. Here, TNFRSF4 is linked to cancer.